2 active not recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Metastatic Gallbladder Carcinoma: new trials by email Literature Review of Metastatic Gallbladder Carcinoma trials Research Report on Metastatic Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
Cholangiocarcinoma (3) · Gallbladder Neoplasms (3) · Neoplasm Metastasis (1)
Adenocarcinoma (3) · Biliary Tract Diseases (3) · Biliary Tract Neoplasms (3) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gallbladder Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Specimen Handling (3) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Gemcitabine (1) · Platinum (1) · Radiation (1) · Radiation Dose Hypofractionation (1) · atezolizumab (1) · avelumab (1) · cobimetinib (1) · durvalumab (1)
National Cancer Institute (NCI) (2) · Ohio State University Comprehensive Cancer Center (1)
United States (3)
Kristen R Spencer (1) · Nilofer S Azad (1) · Sameek Roychowdhury, MD, PhD (1)
UM1CA186644 (1), UM1CA186691 (1), UM1CA186716 (1)